CN104297383A - 一种分离检测阿奇霉素及其杂质的方法 - Google Patents
一种分离检测阿奇霉素及其杂质的方法 Download PDFInfo
- Publication number
- CN104297383A CN104297383A CN201310068514.6A CN201310068514A CN104297383A CN 104297383 A CN104297383 A CN 104297383A CN 201310068514 A CN201310068514 A CN 201310068514A CN 104297383 A CN104297383 A CN 104297383A
- Authority
- CN
- China
- Prior art keywords
- azithromycin
- mobile phase
- impurities
- chromatographic column
- separating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960004099 azithromycin Drugs 0.000 title claims abstract description 65
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 title claims abstract description 65
- 239000012535 impurity Substances 0.000 title claims abstract description 60
- 238000000034 method Methods 0.000 title claims abstract description 34
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims abstract description 90
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims abstract description 45
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims abstract description 32
- 239000000523 sample Substances 0.000 claims abstract description 21
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims abstract description 16
- 235000019253 formic acid Nutrition 0.000 claims abstract description 16
- 238000001514 detection method Methods 0.000 claims abstract description 15
- 239000012488 sample solution Substances 0.000 claims abstract description 11
- 235000011114 ammonium hydroxide Nutrition 0.000 claims abstract description 9
- 238000010828 elution Methods 0.000 claims abstract description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 7
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical group CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 claims abstract description 5
- 238000002360 preparation method Methods 0.000 claims abstract description 5
- 239000011259 mixed solution Substances 0.000 claims abstract description 3
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 claims abstract 4
- 239000000741 silica gel Substances 0.000 claims abstract 3
- 229910002027 silica gel Inorganic materials 0.000 claims abstract 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims abstract 2
- 239000007864 aqueous solution Substances 0.000 claims abstract 2
- 239000000243 solution Substances 0.000 claims description 21
- 239000003643 water by type Substances 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 3
- 101000610640 Homo sapiens U4/U6 small nuclear ribonucleoprotein Prp3 Proteins 0.000 claims description 2
- 101001110823 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-A Proteins 0.000 claims description 2
- 101000712176 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-B Proteins 0.000 claims description 2
- 102100040374 U4/U6 small nuclear ribonucleoprotein Prp3 Human genes 0.000 claims description 2
- 210000000692 cap cell Anatomy 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims 3
- 239000007924 injection Substances 0.000 claims 3
- 238000004807 desolvation Methods 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 abstract description 5
- 238000000825 ultraviolet detection Methods 0.000 abstract description 2
- 230000014759 maintenance of location Effects 0.000 description 24
- 230000000694 effects Effects 0.000 description 16
- 238000000926 separation method Methods 0.000 description 15
- 239000013558 reference substance Substances 0.000 description 10
- 239000003814 drug Substances 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 229940079593 drug Drugs 0.000 description 7
- 150000002500 ions Chemical class 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000004811 liquid chromatography Methods 0.000 description 6
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 239000003513 alkali Substances 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- FZYUKBLYECHAGN-HOQMJRDDSA-N (2r,3s,4r,5r,8r,10r,11r,12s,13s,14r)-2-ethyl-3,4,10-trihydroxy-13-[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-11-[(2s,3r,4s,6r)-3-hydroxy-6-methyl-4-(methylamino)oxan-2-yl]oxy-3,5,6,8,10,12,14-heptamethyl-1-oxa-6-azacyclopentadecan-15-one Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@@H](NC)C[C@@H](C)O2)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 FZYUKBLYECHAGN-HOQMJRDDSA-N 0.000 description 3
- YHVUVJYEERGYNU-UHFFFAOYSA-N 4',8-Di-Me ether-5,7,8-Trihydroxy-3-(4-hydroxybenzyl)-4-chromanone Natural products COC1(C)CC(O)OC(C)C1O YHVUVJYEERGYNU-UHFFFAOYSA-N 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- AJSDVNKVGFVAQU-BIIVOSGPSA-N cladinose Chemical compound O=CC[C@@](C)(OC)[C@@H](O)[C@H](C)O AJSDVNKVGFVAQU-BIIVOSGPSA-N 0.000 description 3
- 229960003276 erythromycin Drugs 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 230000001590 oxidative effect Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- JBYIGHZCRVMHAK-VINPOOLWSA-N (2r,3r,4s,5r,8r,10r,11r,12s,13s,14r)-11-[(2s,3r,4s,6r)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-2-ethyl-4,10-dihydroxy-13-[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,6,8,10,12,14-heptamethyl-1-oxa-6-azacyclopentadecan-15-one Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@H]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)C)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 JBYIGHZCRVMHAK-VINPOOLWSA-N 0.000 description 2
- DEORMZXNPDWMST-BICOPXKESA-N (2s,3r,4s,6r)-2-[[(2r,3s,4r,5r,8r,10r,11r,12s,13s,14r)-2-ethyl-3,4,10-trihydroxy-13-[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,6,8,10,12,14-heptamethyl-15-oxo-1-oxa-6-azacyclopentadec-11-yl]oxy]-3-hydroxy-n,n,6-trimethyloxan-4-amine Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)[N+](C)(C)[O-])O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 DEORMZXNPDWMST-BICOPXKESA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical group O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 2
- MCMNRKCIXSYSNV-UHFFFAOYSA-N Zirconium dioxide Chemical compound O=[Zr]=O MCMNRKCIXSYSNV-UHFFFAOYSA-N 0.000 description 2
- -1 amido azithromycin Chemical compound 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- LLHRMWHYJGLIEV-UHFFFAOYSA-N desoxy Chemical group COC1=CC(CCN)=CC(OC)=C1C LLHRMWHYJGLIEV-UHFFFAOYSA-N 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000003120 macrolide antibiotic agent Substances 0.000 description 2
- 229940041033 macrolides Drugs 0.000 description 2
- FSUFNIVRKKVCSI-HOQMJRDDSA-N n-[(2s,3r,4s,6r)-2-[[(2r,3s,4r,5r,8r,10r,11r,12s,13s,14r)-2-ethyl-3,4,10-trihydroxy-13-[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,6,8,10,12,14-heptamethyl-15-oxo-1-oxa-6-azacyclopentadec-11-yl]oxy]-3-hydroxy-6-methyloxan-4-yl]formami Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@@H](NC=O)C[C@@H](C)O2)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 FSUFNIVRKKVCSI-HOQMJRDDSA-N 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229940072251 zithromax Drugs 0.000 description 2
- HRKNNHYKWGYTEN-HOQMJRDDSA-N (2r,3s,4r,5r,8r,10r,11r,12s,13s,14r)-11-[(2s,3r,4s,6r)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-2-ethyl-3,4,10-trihydroxy-13-[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,8,10,12,14-hexamethyl-1-oxa-6-azacyclopentadecan-15-one Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)NC[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 HRKNNHYKWGYTEN-HOQMJRDDSA-N 0.000 description 1
- PCDDIDGPAIGEHC-GGNUPITBSA-N (2r,3s,4r,5r,8r,10r,11r,12s,13s,14r)-11-[(2s,3r,4s,6r)-4-amino-3-hydroxy-6-methyloxan-2-yl]oxy-2-ethyl-3,4,10-trihydroxy-13-[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,6,8,10,12,14-heptamethyl-1-oxa-6-azacyclopentadecan-15-one Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](C)O2)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 PCDDIDGPAIGEHC-GGNUPITBSA-N 0.000 description 1
- AMNAVVMCWWSBHN-AWHKAWBESA-N (2r,3s,4r,5r,8r,10r,11r,12s,13s,14r)-2-ethyl-3,4,10-trihydroxy-13-[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-11-[(2s,3s,6r)-3-hydroxy-6-methyl-4-oxooxan-2-yl]oxy-3,5,6,8,10,12,14-heptamethyl-1-oxa-6-azacyclopentadecan-15-one Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H](C(=O)C[C@@H](C)O2)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AMNAVVMCWWSBHN-AWHKAWBESA-N 0.000 description 1
- XUKUURHRXDUEBC-SXOMAYOGSA-N (3s,5r)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid Chemical group C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-SXOMAYOGSA-N 0.000 description 1
- OUCSEDFVYPBLLF-KAYWLYCHSA-N 5-(4-fluorophenyl)-1-[2-[(2r,4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-n,4-diphenyl-2-propan-2-ylpyrrole-3-carboxamide Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@H]2OC(=O)C[C@H](O)C2)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 OUCSEDFVYPBLLF-KAYWLYCHSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 238000006237 Beckmann rearrangement reaction Methods 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 229930006677 Erythromycin A Natural products 0.000 description 1
- 241000606790 Haemophilus Species 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 101000748161 Homo sapiens Ubiquitin carboxyl-terminal hydrolase 34 Proteins 0.000 description 1
- 241000589248 Legionella Species 0.000 description 1
- 208000007764 Legionnaires' Disease Diseases 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 102100040048 Ubiquitin carboxyl-terminal hydrolase 35 Human genes 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- AUALQMFGWLZREY-UHFFFAOYSA-N acetonitrile;methanol Chemical group OC.CC#N AUALQMFGWLZREY-UHFFFAOYSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- XYOVOXDWRFGKEX-UHFFFAOYSA-N azepine Chemical compound N1C=CC=CC=C1 XYOVOXDWRFGKEX-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000006652 catabolic pathway Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000003255 drug test Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- QZIQJVCYUQZDIR-UHFFFAOYSA-N mechlorethamine hydrochloride Chemical compound Cl.ClCCN(C)CCCl QZIQJVCYUQZDIR-UHFFFAOYSA-N 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310068514.6A CN104297383B (zh) | 2013-03-04 | 2013-03-04 | 一种分离检测阿奇霉素及其杂质的方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310068514.6A CN104297383B (zh) | 2013-03-04 | 2013-03-04 | 一种分离检测阿奇霉素及其杂质的方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104297383A true CN104297383A (zh) | 2015-01-21 |
CN104297383B CN104297383B (zh) | 2016-03-02 |
Family
ID=52317204
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310068514.6A Active CN104297383B (zh) | 2013-03-04 | 2013-03-04 | 一种分离检测阿奇霉素及其杂质的方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104297383B (zh) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106866790A (zh) * | 2015-12-11 | 2017-06-20 | 北大方正集团有限公司 | 达托霉素RS-5/6、RS-7和RS-7a/7b杂质的制备方法 |
CN109633034A (zh) * | 2019-01-29 | 2019-04-16 | 宜昌东阳光药业股份有限公司 | 阿奇霉素基因毒性杂质的检测方法 |
CN109870528A (zh) * | 2019-02-21 | 2019-06-11 | 北京悦康科创医药科技股份有限公司 | 一种高效液相色谱法测定阿奇霉素胶囊有关物质的方法 |
CN110146599A (zh) * | 2018-02-11 | 2019-08-20 | 齐鲁动物保健品有限公司 | 一种加米霉素的含量检测方法 |
CN111024844A (zh) * | 2019-12-18 | 2020-04-17 | 湖北省宏源药业科技股份有限公司 | 一种阿奇霉素胶囊相关杂质的检测方法 |
CN112697893A (zh) * | 2020-11-27 | 2021-04-23 | 伊犁川宁生物技术股份有限公司 | 一种红霉素菌渣中红霉素a残留效价的测定方法 |
CN112816570A (zh) * | 2020-12-23 | 2021-05-18 | 北京悦康科创医药科技股份有限公司 | 一种阿奇霉素有关物质的检测方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011015219A1 (en) * | 2009-08-06 | 2011-02-10 | Shifa Pharmed Industrial Group Co. | Process for the purification of azithromycin by separation from its thermal degradation products and/or isomers |
CN102590392A (zh) * | 2012-03-14 | 2012-07-18 | 齐鲁制药有限公司 | 一种阿奇霉素缓释滴眼液中阿奇霉素的含量测定方法 |
-
2013
- 2013-03-04 CN CN201310068514.6A patent/CN104297383B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011015219A1 (en) * | 2009-08-06 | 2011-02-10 | Shifa Pharmed Industrial Group Co. | Process for the purification of azithromycin by separation from its thermal degradation products and/or isomers |
CN102590392A (zh) * | 2012-03-14 | 2012-07-18 | 齐鲁制药有限公司 | 一种阿奇霉素缓释滴眼液中阿奇霉素的含量测定方法 |
Non-Patent Citations (5)
Title |
---|
D. DEBREMAEKER等: "Analysis of unknown compounds in azithromycin bulk samples with liquid chromatography coupled to ion trap mass spectrometry", 《RAPID COMMUNICATIONS IN MASS SPECTROMETRY》, vol. 17, 31 December 2003 (2003-12-31), pages 342 - 350 * |
FUAD AL-RIMAWI等: "Analysis of Azithromycin and Its Related Compounds by RP-HPLC with UV Detection", 《JOURNAL OF CHROMATOGRAPHIC SCIENCE》, vol. 48, 28 February 2010 (2010-02-28), pages 86 - 90 * |
张斗胜等: "国产注射用阿奇霉素杂质谱及其与成盐工艺相关性的考察", 《药物分析杂志》, vol. 31, no. 8, 31 December 2011 (2011-12-31), pages 1521 - 1526 * |
王明娟等: "HPLC法分析阿奇霉素及各类注射剂中有关物质的含量", 《HPLC 法分析阿奇霉素及各类注射剂中有关物质的含量》, vol. 33, no. 12, 31 December 2008 (2008-12-31), pages 740 - 745 * |
郑白水等: "注射用乳糖酸阿奇霉素的有关物质测定", 《中国药业》, vol. 20, no. 5, 31 December 2011 (2011-12-31), pages 24 - 25 * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106866790A (zh) * | 2015-12-11 | 2017-06-20 | 北大方正集团有限公司 | 达托霉素RS-5/6、RS-7和RS-7a/7b杂质的制备方法 |
CN110146599A (zh) * | 2018-02-11 | 2019-08-20 | 齐鲁动物保健品有限公司 | 一种加米霉素的含量检测方法 |
CN109633034A (zh) * | 2019-01-29 | 2019-04-16 | 宜昌东阳光药业股份有限公司 | 阿奇霉素基因毒性杂质的检测方法 |
CN109633034B (zh) * | 2019-01-29 | 2021-05-14 | 宜昌东阳光生化制药有限公司 | 阿奇霉素基因毒性杂质的检测方法 |
CN109870528A (zh) * | 2019-02-21 | 2019-06-11 | 北京悦康科创医药科技股份有限公司 | 一种高效液相色谱法测定阿奇霉素胶囊有关物质的方法 |
CN111024844A (zh) * | 2019-12-18 | 2020-04-17 | 湖北省宏源药业科技股份有限公司 | 一种阿奇霉素胶囊相关杂质的检测方法 |
CN112697893A (zh) * | 2020-11-27 | 2021-04-23 | 伊犁川宁生物技术股份有限公司 | 一种红霉素菌渣中红霉素a残留效价的测定方法 |
CN112816570A (zh) * | 2020-12-23 | 2021-05-18 | 北京悦康科创医药科技股份有限公司 | 一种阿奇霉素有关物质的检测方法 |
CN112816570B (zh) * | 2020-12-23 | 2022-10-28 | 北京悦康科创医药科技股份有限公司 | 一种阿奇霉素有关物质的检测方法 |
Also Published As
Publication number | Publication date |
---|---|
CN104297383B (zh) | 2016-03-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104297383A (zh) | 一种分离检测阿奇霉素及其杂质的方法 | |
Rosén et al. | Determination of the neurotoxin BMAA (β-N-methylamino-L-alanine) in cycad seed and cyanobacteria by LC-MS/MS (liquid chromatography tandem mass spectrometry) | |
Zheng et al. | In-tube solid-phase microextraction based on hybrid silica monolith coupled to liquid chromatography–mass spectrometry for automated analysis of ten antidepressants in human urine and plasma | |
Dasgupta¹ | Advances in antibiotic measurement | |
Wu et al. | Simultaneous determination of amantadine, rimantadine and memantine in chicken muscle using multi-walled carbon nanotubes as a reversed-dispersive solid phase extraction sorbent | |
WO2018107975A1 (zh) | 一种右丙亚胺的分析方法 | |
Varga et al. | Determination of antihypertensive and anti-ulcer agents from surface water with solid-phase extraction–liquid chromatography–electrospray ionization tandem mass spectrometry | |
Zhang et al. | Derivatization for the simultaneous LC/MS quantification of multiple neurotransmitters in extracellular fluid from rat brain microdialysis | |
CN103776928B (zh) | 一种检测尿液中3-羟基可替宁的方法 | |
Liu et al. | Studies on the chiral separation of pheniramine and its enantioselective pharmacokinetics in rat plasma by HPLC-MS/MS | |
KR20070011572A (ko) | 매크롤리드 및 이들의 불순물의 검출, 확인 및 정량 방법및 시스템 | |
Du et al. | Enantioselective determination of ornidazole in human plasma by liquid chromatography–tandem mass spectrometry on a Chiral-AGP column | |
Yuan et al. | Impurity profiling of etimicin sulfate by liquid chromatography ion-trap mass spectrometry | |
CN111060621B (zh) | 一种注射用头孢哌酮钠舒巴坦钠有关物质的检测方法 | |
Attema-de Jonge et al. | Simple and sensitive method for quantification of low tobramycin concentrations in human plasma using HPLC–MS/MS | |
CN101929985A (zh) | 一种用高效液相色谱法测定阿托伐他汀钙有关物质的方法 | |
Ji et al. | A modified QuEChERS method based on a reduced graphene oxide-coated melamine sponge for multiresidue analysis of veterinary drugs in mutton by UPLC–MS/MS | |
CN108333272A (zh) | Lc-msms法分离测定对氨基水杨酸及其相关杂质的方法 | |
Heaton et al. | Systematic evaluation of acetone and acetonitrile for use in hydrophilic interaction liquid chromatography coupled with electrospray ionization mass spectrometry of basic small molecules | |
WO2023272962A1 (zh) | 甲磺酸帕珠沙星原料药中小极性杂质的检测方法 | |
Bharathi et al. | Quantification of montelukast, a selective cysteinyl leukotriene receptor (CysLT1) antagonist in human plasma by liquid chromatography–mass spectrometry: validation and its application to a human pharmacokinetic study | |
Vučičevič-Prčetič et al. | Determination of neomycin and oxytetracycline in the presence of their impurities in veterinary dosage forms by high-performance liquid chromatography/tandem mass spectrometry | |
CN111751482A (zh) | 一种同步检测养猪废水中多类抗生素残留量的方法 | |
Fang et al. | Liquid chromatography/quadrupole time-of-flight mass spectrometry for determination of saxitoxin and decarbamoylsaxitoxin in shellfish | |
Sri et al. | Application of newly developed and validated LC-MS/MS method for pharmacokinetic study of adagrasib and pembrolizumab simultaneously in rat plasma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20180619 Address after: 226133 room 2, No. 3, Ling Dian Industrial Zone, Linjiang Town, Haimen, Nantong, Jiangsu. Patentee after: Shanghai Shyndec Pharmaceutical Co., Ltd Address before: No. 1320, Beijing West Road, Jing'an District, Shanghai City, Shanghai Co-patentee before: China State Institute of Pharmaceutical Industry Patentee before: Shanghai Institute of pharmaceutical industry |
|
TR01 | Transfer of patent right | ||
CP03 | Change of name, title or address |
Address after: 226133 No.1, Linjiang Avenue, Linjiang Town, Haimen District, Nantong City, Jiangsu Province Patentee after: Jiangsu Weiqida Pharmaceutical Co., Ltd Address before: 226133 room 2, No. 3, Ling Dian Industrial Zone, Linjiang Town, Haimen, Nantong, Jiangsu. Patentee before: SHANGHAI SHYNDEC PHARMACEUTICAL Co.,Ltd. |
|
CP03 | Change of name, title or address |